References
- Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112(1):18–35. doi: 10.1038/ajg.2016.517
- Karmen A, Wroblewski F, Ladue JS. Transaminase activity in human blood. J Clin Invest. 1955;34(1):126–131. doi: 10.1172/JCI103055
- Dufour DR, Lott JA, Nolte FS, et al. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem. 2000;46(12):2050–2068. doi: 10.1093/clinchem/46.12.2050
- Matsushita M, Komoda T. Relationship between the effects of a high-fat meal and blood group in determination of alkaline phosphatase activity. Rinsho Byori. 2011;59(10):923–929.
- Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012;156(4):263–270. doi: 10.7326/0003-4819-156-4-201202210-00378
- Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association. Hepatology. 2012;55(6):2005–2023. doi: 10.1002/hep.25762
- Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’. Gut. 2015;64(11):1671–1672. doi: 10.1136/gutjnl-2015-310593
- Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950–967. doi: 10.1038/ajg.2014.131
- Horn SR, Stoltzfus KC, Lehrer EJ, et al. Epidemiology of liver metastases. Cancer Epidemiol. 2020;67:101760. doi: 10.1016/j.canep.2020.101760
- Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–285. doi: 10.1111/j.1365-2036.2011.04724.x
- Alberti KG, Zimmet P, Shaw J. Metabolic syndrome–a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23(5):469–480. doi: 10.1111/j.1464-5491.2006.01858.x
- Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009;13(1):9–19.
- Clark AM, Ma B, Taylor DL, et al. Liver metastases: Microenvironments and ex-vivo models. Exp Biol Med (Maywood). 2016;241(15):1639–1652. doi: 10.1177/1535370216658144
- Aldrighetti L, Castoldi R, Di Palo S, et al. Fattori prognostici dell’outcome a lungo termine della chirurgia resettiva epatica per metastasi da carcinoma colorettale [Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases]. Chir Ital. 2005;57(5):555–570.
- Kemeny NE, Kemeny M, Lawrence TS. Liver metastases. In: Abeloff M, editor. Clinical oncology. (NY): Churchill Livingstone; 2000. p. 886–914.
- Blendis LM. Review article: the treatment of alcoholic liver disease. Aliment Pharmacol Ther. 1992;6(5):541–548. doi: 10.1111/j.1365-2036.1992.tb00568.x
- Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005;172(3):367–379. doi: 10.1503/cmaj.1040752
- Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroenterol. 2010;105(5):978–80. doi: 10.1038/ajg.2010.102
- Bunchorntavakul C, Reddy KR. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther. 2013;37(1):3–17. doi: 10.1111/apt.12109
- Gonullu H, Karadas S, Dulger AC, et al. Hepatotoxicity associated with the ingestion of Papaver Rhoease. J Pak Med Assoc. 2014;64(10):1189–1190.
- Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261–280. doi: 10.1038/nrgastro.2016.51
- Abraham NS, Barkun JS, Barkun AN. Palliation of malignant biliary obstruction: a prospective trial examining impact on quality of life. Gastrointest Endosc. 2002;56(6):835–841. doi: 10.1016/S0016-5107(02)70356-8
- Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park). 2005;19(8):1057–1069.
- Baron TH. Palliation of malignant obstructive jaundice. Gastroenterol Clin North Am. 2006;35(1):101–112. doi: 10.1016/j.gtc.2006.01.001
- Kimura Y, Takada T, Kawarada Y, et al. Definitions, pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo guidelines. J Hepatobiliary Pancreat Surg. 2007;14(1):15–26. doi: 10.1007/s00534-006-1152-y
- Yeom DH, Oh HJ, Son YW, et al. What are the risk factors for acute suppurative cholangitis caused by common bile duct stones? Gut Liver. 2010;4(3):363–367. doi: 10.5009/gnl.2010.4.3.363
- Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–1555. doi: 10.1016/S0140-6736(15)61412-X
- Mui UN, Haley CT, Tyring SK. Viral oncology: molecular biology and pathogenesis. J Clin Med. 2017;6(12):111. doi: 10.3390/jcm6120111
- McLernon DJ, Donnan PT, Ryder S, et al. Health outcomes following liver function testing in primary care: a retrospective cohort study. Fam Pract. 2009;26(4):251–259. doi: 10.1093/fampra/cmp025
- Pendino GM, Mariano A, Surace P, et al. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology. 2005;41(5):1151–1159. doi: 10.1002/hep.20689
- Harjola VP, Mullens W, Banaszewski M, et al. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the acute heart failure committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017;19(7):821–836. doi: 10.1002/ejhf.872
- Miyama H, Shiraishi Y, Kohsaka S, et al. Abnormal liver function tests and long-term outcomes in patients discharged after acute heart failure. J Clin Med. 2021;10(8):1730. doi: 10.3390/jcm10081730
- Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc. 2014;89(1):95–106. doi: 10.1016/j.mayocp.2013.09.016
- Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354(7):731–739. doi: 10.1056/NEJMra052270
- Donate-Moreno MJ, Lorenzo-Sánchez MV, Díaz de Mera-Sánchez Migallón I, et al. Inflammatory markers as prognostic factors in metastatic castration-resistant prostate cancer. Marcadores inflamatorios como factor pronóstico en el cáncer de próstata resistente a la castración metastásico. Actas Urol Esp (Engl Ed). 2020;44(10):692–700. doi: 10.1016/j.acuro.2020.08.001